Abstract:New approaches / strategies to develop potential anticancer agents are necessary not only to address the increasing incidences of cancer worldwide but also to overcome the multifaceted problem of drug resistance. SIRT1, the most widely studied among all the sirtuins plays an important role in cancer and is considered as a promising pharmacological target for this disease. A new framework based on 2-arylamino-3-cyanopyridine was designed and assessed in silico for the identification of new and potential inhibitors of SIRT1. Initially, docking of a series of representative molecules in silico not only indicated their encouraging interactions with SIRT1 but also suggested their potential selectivity towards this protein over SIRT2. The study also suggested that H-bonding with residues ASN346 and ALA262 and other interactions with residues PHE273, PHE297, ILE411, ILE347, HIS363, GLN345 etc were common for several of these molecules. Thus, a library of molecules based on the designed framework was constructed for further pharmacological studies. These molecules were accessed conveniently via the ultrasound assisted 4-component reaction of appropriate ketone, aldehyde, aromatic amine and malononitrile in aqueous media under open air. The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recoverable acidic catalyst for this purpose. The catalyst was recovered and recycled for a number of times without significant loss of its catalytic activity. A range of 2-arylamino-3-cyanopyridine derivatives were prepared in good (82–91%) yields using this green reaction. In vitro evaluation of these pyridine derivatives against SIRT1 revealed encouraging inhibitory activities (> 50% inhibition) thereby corroborating the outcome of docking studies. Indeed, the compounds 5a, 5g and 5j identified as most promising in the in silico docking studies were also found to be the most active pyridine derivatives in this in vitro assay. The Structure-Activity-Relationship (SAR) study revealed that an aryl group at C-4 position of the central pyridine ring was preferred over the heteroaryl or alkyl moiety whereas an unsubstituted benzene ring was favored over a substituted one at the C-6 position. Similarly, an unsubstituted phenyl group appeared to be better than the substituted one for the arylamino moiety at C-2 position. The reason for lower activity for a particular molecule was also investigated via in silico studies. Overall, according to the in silico as well as in vitro studies the pyridine derivatives 5a, 5g and 5j appeared as most potent among the compounds tested that were found to be several fold more potent than the known pyridine based inhibitor nicotinamide.

Design and synthesis of amino acid derivatives of substituted benzimidazoles and pyrazoles as Sirt1 inhibitors

Design and Synthesis of Amino Acid Derivatives of Substituted Benzimidazoles and Pyrazoles as Selective Sirt1 Inhibitors

Discovery of 5-(Substituted Phenyl)-2-aryl Benzimidazole Derivatives as SIRT1 Activators: Their Design, in silico Studies, Synthesis, and in vitro Evaluation

Design, synthesis and biological evaluation of 2,4,6- trisubstituted triazine derivatives as new nonpeptide small-molecule SIRT5 inhibitors

Pharmacophore-guided in-silico discovery of SIRT1 inhibitors for targeted cancer therapy

Design, synthesis, and biological screening of a series of pyrazolo [1,5-a]quina-zoline derivatives as SIRT6 activators

Design, synthesis, and pharmacological evaluations of pyrrolo[1,2- a ]quinoxaline-based derivatives as potent and selective sirt6 activators

Computational Design and Optimization of Peptide Inhibitors for SIRT2

Targeting Sirtuin 1 for therapeutic potential: Drug repurposing approach integrating docking and molecular dynamics simulations

A sonochemical approach to 4-substituted pyrrolo[1,2- a ]quinoxalines via Cu-catalyzed N -arylation followed by Wang resin/air promoted oxidative cyclization strategy

Wang-OSO3H catalyzed green synthesis of 2-arylamino-3-cyanopyridine derivatives under ultrasound: Their assessment as potential inhibitors of SIRT1

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD + -Dependent Lysine Deacylase Sirtuin 2

Molecular Modeling, Chemical Synthesis and Biological Assays

Research and study of 2-((4,6 dimethyl pyrimidine-2-yle) thio)-N-phenyl acetamide derivatives as inhibitors of sirtuin 2 protein for the treatment of cancer using QSAR, molecular docking and molecular dynamic simulation

A pharmacological review on SIRT 1 and SIRT 2 proteins, activators, and inhibitors: Call for further research

Design, synthesis and biological evaluation of prostate-specific membrane antigen (PSMA)-targeted SIRT2 inhibitors

Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators

Structure-activity studies of 1,2,4-oxadiazoles for the inhibition of the NAD+ dependent lysine deacylase Sirtuin2

Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-n-phenylacetamide Derivatives As New Potent and Selective Human Sirtuin 2 Inhibitors

Activation and inhibition of sirtuins: From bench to bedside